During the past decade, Instituto Nacional de Cancerología conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 8 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional de Cancerología" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Instituto Nacional de Cancerologia, Columbia" with 5 trials sponsored, "M.D. Anderson Cancer Center" with 2 trials sponsored, "National Cancer Institute (NCI)" with 2 trials sponsored and "SWOG Cancer Research Network" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional de Cancerología" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Agency for Healthcare Research and Quality (AHRQ)" with 1 trials as a collaborator, "Chiba University, Japan" with 1 trials as a collaborator and "ETOP IBCSG Partners Foundation" with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional de Cancerología" are "Breast Cancer" (3 trials), "Colonic Neoplasms" (2 trials), "Multiple Myeloma" (2 trials), "Anatomic Stage I Breast Cancer AJCC v8" (1 trials) and "Anatomic Stage IA Breast Cancer AJCC v8" (1 trials). Many other conditions were trialed in "Instituto Nacional de Cancerología" in a lesser frequency.

Most popular intervention types in "Instituto Nacional de Cancerología" are "Drug" (15 trials), "Other" (6 trials), "Procedure" (3 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pertuzumab" (3 trials), "Placebo" (3 trials), "Atezolizumab" (2 trials), "Bevacizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional de Cancerología" are 18 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Nacional de Cancerología". undefined are not yet recruiting, undefined are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Instituto Nacional de Cancerología, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional de Cancerología, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 7 trials that are defined as “Not Applicable".